Loading...
•
Sep 27, 2025
Charles River Labs Q3 2025 Earnings Report
Charles River Labs reported third-quarter 2025 results with a slight revenue decline and reduced profitability, but saw strong performance in its RMS segment.
Key Takeaways
Charles River Laboratories posted Q3 2025 revenue of $1.00 billion, down 0.5% YoY, with GAAP net income falling to $54.4 million. Despite headwinds, the company saw strength in Research Models and Services. Guidance was tightened, reflecting cautious optimism.
Revenue reached $1.00 billion, a slight YoY decline of 0.5%.
GAAP EPS was $1.10, and non-GAAP EPS was $2.43.
Net income fell to $54.4 million due to investment losses.
RMS segment posted strong growth, offsetting DSA and Manufacturing weakness.
Revenue by Segment
Forward Guidance
Full-year 2025 revenue and EPS guidance were narrowed to reflect slightly better Q3 performance, with optimism tempered by continued sector uncertainty.
Positive Outlook
- 2025 revenue guidance narrowed upward to (1.5)% – (0.5)%
- Non-GAAP EPS guidance raised to $10.10 – $10.30
- Lower restructuring and interest expenses aided earnings
- Stock repurchases reduced diluted shares outstanding
- Positive signals in early-stage research demand
Challenges Ahead
- Organic revenue still expected to decline by 2.5%–1.5%
- Higher tax rate impacted non-GAAP earnings
- Venture capital losses reduced GAAP net income
- DSA and Manufacturing segments faced revenue headwinds
- Healthcare sector uncertainty continues to weigh on outlook
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...